Pharma News News 2 December 2025

Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma A/S (NASDAQ: ASND) is back in the spotlight on December 9, 2025, after its share price slipped again while Wall Street continues to project hefty upside and label the name a “Buy” or “Strong Buy.” The Danish biotech,

9 December 2025

Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly and Company (NYSE: LLY) is once again in the spotlight. As of early trading on December 9, 2025, Eli Lilly stock is hovering around $997 per share, roughly 10% below its late‑November all‑time high but still up about

9 December 2025

Drug Developments · Investment Insights · Market Outlook · NYSE:LLY · Pharma News · Stock Analysis

(OCUL) Stock Soars on Accelerated Wet AMD NDA – Price, Forecast & Risk Analysis as of December 9, 2025

All figures and opinions reflect information available on December 9, 2025 and may change over time. This article is for informational purposes only and is not investment advice. OCUL Stock Today: A 52‑Week High After a Single Press Release Ocular

9 December 2025

Biotechnology Stocks · Market Updates · NASDAQ:OCUL · Pharma News · Price Forecasts · Risk Analysis

Natco Pharma Share Price Today (8 December 2025): Q2 Results, Adcock Ingram Deal and 2026 Stock Outlook

Natco Pharma Limited (NSE: NATCOPHARM) is back in the spotlight as the stock trades lower on 8 December 2025 even while the company closes a landmark acquisition in South Africa and navigates life after its blockbuster Revlimid (lenalidomide) windfall. Around

8 December 2025

Business Deals · Investment Insights · Pharma News · Q2 Results · Stock Market

Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb (NYSE: BMY) has packed a lot into the first week of December 2025 – from a surprise update on a key Alzheimer’s drug trial to major hematology data at ASH 2025 and a legal setback over its

7 December 2025

Clinical Trials · Investment Analysis · Legal Issues · NYSE:BMY · Pharma News · Stock Market

RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)

Recursion Pharmaceuticals (NASDAQ: RXRX), one of the highest‑profile AI‑driven drug discovery names, is back under the microscope. As of the December 5, 2025 close, RXRX stock traded around $4.71, giving the company a market capitalization of roughly $2.5 billion and

7 December 2025

CEO Changes · Insider Activity · Market Outlook · NASDAQ:RXRX · Pharma News · Stock Analysis

Ocular Therapeutix (OCUL) Stock News Today: Price, Forecast and Analysis as AXPAXLI NDA Plan Emerges

As of the close on Friday, December 5, 2025, Ocular Therapeutix, Inc. (NASDAQ: OCUL) finished regular trading at $12.58 per share, up about 1.2% on the day, with after‑hours quotes on some platforms briefly touching the $14 area. StockAnalysis+1 The

6 December 2025

Biotechnology · Financial Forecasts · Investment Analysis · NASDAQ:OCUL · Pharma News · Stock Market

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon Ltd. (NASDAQ: PLRZ) has gone from obscure micro‑cap to headline‑grabbing biotech in just two trading days. On December 4, 2025, the stock was changing hands in the mid‑teens, more than doubling from the prior close of $7.09, with intraday

4 December 2025

Biotechnology · Healthcare Innovation · Investment Tips · NASDAQ:PLRZ · Pharma News · Stock Market

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

Updated: December 4, 2025 Key takeaways CRISPR Therapeutics stock today: price, volatility and positioning As of pre‑market trading on December 4, 2025, CRISPR Therapeutics AG (NASDAQ: CRSP) is changing hands at roughly $56, just above Wednesday’s close of $55.99, after

4 December 2025

Biotechnology · Investing · Market Analysis · NASDAQ:CRSP · Pharma News · Stocks

Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Updated: December 4, 2025 – mid‑day U.S. trading Capricor Therapeutics, Inc. (NASDAQ: CAPR) has just pulled off the kind of move small‑cap biotech traders dream about and risk managers lose sleep over. After releasing decisive Phase 3 data for its

4 December 2025

Analyst Ratings · Biotechnology · Investment Insights · NASDAQ:CAPR · Pharma News · Stock Market

GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts

As of December 3, 2025, GSK plc (LSE:GSK, NYSE:GSK) is trading near multi‑year highs after a year of earnings beats, a revived oncology franchise, heavy share buybacks and an unusually busy FDA calendar for December. At the same time, analysts

3 December 2025

FDA Updates · Investment Strategies · Market Forecasts · NYSE:GSK · Pharma News · Stock Analysis

Natco Pharma Share Price Today (2 December 2025): Rating Reaffirmed, USFDA Update, South Africa Deal and 2026 Stock Forecast

Natco Pharma has had a busy few months: a big overseas acquisition in South Africa, a fresh USFDA inspection with Form 483 observations, strong-but-normalising earnings, and a credit-rating reaffirmation that reassured debt markets. The share price is finally stabilising after

2 December 2025

Financial Analysis · Global Business · Investment Tips · Pharma News · Stock Market

Pharma News News 2 December 2025 - 9 December 2025